153 related articles for article (PubMed ID: 36106407)
1. Combination of Circulating Cell-Free DNA and Positron Emission Tomography to Distinguish Non-Small Cell Lung Cancer from Tuberculosis.
Zheng W; Quan B; Gao G; Zhang P; Huang L
Lab Med; 2023 Mar; 54(2):130-141. PubMed ID: 36106407
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of circulating cell-free DNA quantification and metabolic tumor burden in advanced non-small cell lung cancer.
Hyun MH; Lee ES; Eo JS; Kim S; Kang EJ; Sung JS; Choi YJ; Park KH; Shin SW; Lee SY; Kim YH
Lung Cancer; 2019 Aug; 134():158-166. PubMed ID: 31319975
[TBL] [Abstract][Full Text] [Related]
3. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis.
Leng S; Zheng J; Jin Y; Zhang H; Zhu Y; Wu J; Xu Y; Zhang P
Clin Chim Acta; 2018 Feb; 477():160-165. PubMed ID: 29113814
[TBL] [Abstract][Full Text] [Related]
4. Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer:
Morbelli S; Alama A; Ferrarazzo G; Coco S; Genova C; Rijavec E; Bongioanni F; Biello F; Dal Bello MG; Barletta G; Massollo M; Vanni I; Piva R; Nieri A; Bauckneht M; Sambuceti G; Grossi F
J Nucl Med; 2017 Nov; 58(11):1764-1769. PubMed ID: 28450567
[TBL] [Abstract][Full Text] [Related]
5. The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC.
Nygaard AD; Holdgaard PC; Spindler KL; Pallisgaard N; Jakobsen A
Br J Cancer; 2014 Jan; 110(2):363-8. PubMed ID: 24231948
[TBL] [Abstract][Full Text] [Related]
6. Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients.
Winther-Larsen A; Demuth C; Fledelius J; Madsen AT; Hjorthaug K; Meldgaard P; Sorensen BS
Br J Cancer; 2017 Aug; 117(5):704-709. PubMed ID: 28683468
[TBL] [Abstract][Full Text] [Related]
7. Cell-free DNA concentration and fragment size fraction correlate with FDG PET/CT-derived parameters in NSCLC patients.
González de Aledo-Castillo JM; Casanueva-Eliceiry S; Soler-Perromat A; Fuster D; Pastor V; Reguart N; Viñolas N; Reyes R; Vollmer I; Paredes P; Puig-Butillé JA
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3631-3642. PubMed ID: 33797597
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
[TBL] [Abstract][Full Text] [Related]
9. Combining
Woff E; Kehagias P; Vandeputte C; Ameye L; Guiot T; Paesmans M; Hendlisz A; Flamen P
J Nucl Med; 2019 Oct; 60(10):1366-1372. PubMed ID: 30850494
[TBL] [Abstract][Full Text] [Related]
10. Fluorodeoxyglucose positron emission tomography and chemotherapy-related tumor marker expression in non-small cell lung cancer.
Duan XY; Wang W; Wang JS; Shang J; Gao JG; Guo YM
BMC Cancer; 2013 Nov; 13():546. PubMed ID: 24237755
[TBL] [Abstract][Full Text] [Related]
11. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
12. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
Dong X; Wu P; Sun X; Li W; Wan H; Yu J; Xing L
J Med Imaging Radiat Oncol; 2015 Jun; 59(3):338-45. PubMed ID: 25708154
[TBL] [Abstract][Full Text] [Related]
13. PET morphology helps distinguish solitary and solid pulmonary tuberculosis from non-small cell lung cancer.
Li Q; Li Y; Yuan H; Yang F; Huang Y; Song X; Jiang L
Jpn J Radiol; 2023 Mar; 41(3):312-321. PubMed ID: 36227458
[TBL] [Abstract][Full Text] [Related]
14. The association of 18F-deoxyglucose (FDG) uptake of PET with polymorphisms in the glucose transporter gene (SLC2A1) and hypoxia-related genes (HIF1A, VEGFA, APEX1) in non-small cell lung cancer. SLC2A1 polymorphisms and FDG-PET in NSCLC patients.
Kim SJ; Hwang SH; Kim IJ; Lee MK; Lee CH; Lee SY; Lee EY
J Exp Clin Cancer Res; 2010 Jun; 29(1):69. PubMed ID: 20540786
[TBL] [Abstract][Full Text] [Related]
15. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
Ai B; Liu H; Huang Y; Peng P
Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
[TBL] [Abstract][Full Text] [Related]
16. Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules.
Szpechcinski A; Rudzinski P; Kupis W; Langfort R; Orlowski T; Chorostowska-Wynimko J
Cancer Lett; 2016 May; 374(2):202-7. PubMed ID: 26854716
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
18. The expression of miRNA-216b is negatively correlated with 18F-FDG uptake in non-small cell lung cancer.
Zuo M; Yao L; Wen L; Shen J; Zhang N; Bai T; Huang Q
World J Surg Oncol; 2021 Sep; 19(1):262. PubMed ID: 34470640
[TBL] [Abstract][Full Text] [Related]
19. Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib.
Winther-Larsen A; Fledelius J; Sorensen BS; Meldgaard P
Lung Cancer; 2016 Apr; 94():81-7. PubMed ID: 26973211
[TBL] [Abstract][Full Text] [Related]
20. Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer.
Bian J; Yan K; Liu N; Xu X
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2621-2630. PubMed ID: 32661602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
